132 related articles for article (PubMed ID: 38884866)
1. In vivo stable
Suzuki H; Kannaka K; Hirayama M; Yamashita T; Kaizuka Y; Kobayashi R; Yasuda T; Takahashi K; Uehara T
EJNMMI Radiopharm Chem; 2024 Jun; 9(1):48. PubMed ID: 38884866
[TBL] [Abstract][Full Text] [Related]
2. Neopentyl glycol-based radiohalogen-labeled amino acid derivatives for cancer radiotheranostics.
Kaizuka Y; Suzuki H; Watabe T; Ooe K; Toyoshima A; Takahashi K; Sawada K; Iimori T; Masuda Y; Uno T; Kannaka K; Uehara T
EJNMMI Radiopharm Chem; 2024 Feb; 9(1):17. PubMed ID: 38407647
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and preliminary evaluation of
Vaidyanathan G; Mease RC; Minn I; Choi J; Chen Y; Shallal H; Kang CM; McDougald D; Kumar V; Pomper MG; Zalutsky MR
Nucl Med Biol; 2021; 94-95():67-80. PubMed ID: 33601187
[TBL] [Abstract][Full Text] [Related]
4. Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors.
Vaidyanathan G; Kang CM; McDougald D; Minn I; Brummet M; Pomper MG; Zalutsky MR
Nucl Med Biol; 2018; 62-63():18-30. PubMed ID: 29803076
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature.
Ha H; Kwon H; Lim T; Jang J; Park SK; Byun Y
Expert Opin Ther Pat; 2021 Jun; 31(6):525-547. PubMed ID: 33459068
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and preclinical evaluation of novel
Robu S; Schmidt A; Eiber M; Schottelius M; Günther T; Hooshyar Yousefi B; Schwaiger M; Wester HJ
EJNMMI Res; 2018 Apr; 8(1):30. PubMed ID: 29651565
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of a New Series of Albumin-Binding
Boinapally S; Alati S; Jiang Z; Yan Y; Lisok A; Singh R; Lofland G; Minn I; Hobbs RF; Pomper MG; Banerjee SR
Molecules; 2023 Aug; 28(16):. PubMed ID: 37630410
[TBL] [Abstract][Full Text] [Related]
8.
Abouzayed A; Seitova K; Lundmark F; Bodenko V; Oroujeni M; Tolmachev V; Rosenström U; Orlova A
Front Oncol; 2023; 13():1221103. PubMed ID: 37829345
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with
van der Doelen MJ; Mehra N; van Oort IM; Looijen-Salamon MG; Janssen MJR; Custers JAE; Slootbeek PHJ; Kroeze LI; Bruchertseifer F; Morgenstern A; Haberkorn U; Kratochwil C; Nagarajah J; Gerritsen WR
Urol Oncol; 2021 Oct; 39(10):729.e7-729.e16. PubMed ID: 33353867
[TBL] [Abstract][Full Text] [Related]
10. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
11. Neopentyl Glycol as a Scaffold to Provide Radiohalogenated Theranostic Pairs of High
Suzuki H; Kaizuka Y; Tatsuta M; Tanaka H; Washiya N; Shirakami Y; Ooe K; Toyoshima A; Watabe T; Teramoto T; Sasaki I; Watanabe S; Ishioka NS; Hatazawa J; Uehara T; Arano Y
J Med Chem; 2021 Nov; 64(21):15846-15857. PubMed ID: 34708646
[TBL] [Abstract][Full Text] [Related]
12. Advances in
Ling SW; de Blois E; Hooijman E; van der Veldt A; Brabander T
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297601
[TBL] [Abstract][Full Text] [Related]
13. Development and Preclinical Evaluation of [
El Fakiri M; Ayada N; Müller M; Hvass L; Gamzov TH; Clausen AS; Geis NM; Steinacker N; Hansson E; Lindegren S; Aneheim E; Jensen H; Eder AC; Jensen AI; Poulie CBM; Kjaer A; Eder M; Herth MM
J Nucl Med; 2024 Apr; 65(4):593-599. PubMed ID: 38423784
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
15. Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer.
Ritawidya R; Wongso H; Effendi N; Pujiyanto A; Lestari W; Setiawan H; Humani TS
Adv Pharm Bull; 2023 Nov; 13(4):701-711. PubMed ID: 38022814
[TBL] [Abstract][Full Text] [Related]
16. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
[TBL] [Abstract][Full Text] [Related]
17. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U
J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
[No Abstract] [Full Text] [Related]
19. Long-term survival outcomes of salvage [
Ballal S; Yadav MP; Satapathy S; Raju S; Tripathi M; Damle NA; Sahoo RK; Bal C
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3777-3789. PubMed ID: 37462775
[TBL] [Abstract][Full Text] [Related]
20. Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of
Belli ML; Sarnelli A; Mezzenga E; Cesarini F; Caroli P; Di Iorio V; Strigari L; Cremonesi M; Romeo A; Nicolini S; Matteucci F; Severi S; Paganelli G
Front Oncol; 2020; 10():531660. PubMed ID: 33251129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
